{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Previously+Untreated+Stage+IV+Non-Squamous+Non+Small+Cell+Lung+Cancer", "query": { "condition": "Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T21:43:51.260Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT00666692", "title": "A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-04", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-04-27", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Yakima", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666692" }, { "nct_id": "NCT01829113", "title": "Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Squamous Non Small Cell Lung Cancer" ], "interventions": [ { "name": "OGX-427", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2013-07", "completion_date": "2017-04-19", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 16, "location_summary": "Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829113" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT01820325", "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lunch Cancer" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Buparlisib placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2013-09-09", "completion_date": "2014-06-18", "has_results": false, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Portland, Oregon", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820325" }, { "nct_id": "NCT02087241", "title": "Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" }, { "name": "AZD1775 Matching Placebo", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 8, "location_summary": "Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087241" }, { "nct_id": "NCT00970684", "title": "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nathan Pennell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2009-09", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2022-08-16", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 4, "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Mayfield Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970684" }, { "nct_id": "NCT01082549", "title": "Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Lung Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "gemcitabine/carboplatin plus Iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2010-03", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082549" }, { "nct_id": "NCT05513703", "title": "A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Telisotuzumab Vedotin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2022-11-21", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-06-10T21:43:51.260Z", "location_count": 2, "location_summary": "Los Alamitos, California • Renton, Washington", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05513703" } ] }